ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

θ°©ÊõºóXelox·½°¸Í¬ÆÚÁªºÏÊÊÐε÷Ç¿·ÅÁƵÄÁÙ´²¹Û²ì_ÁÙ´²Ò½Ñ§×¨Òµ±ÏÒµÂÛÎÄ·¶ÎÄ

·¢²¼Ê±¼ä£º2014-12-07 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
θ°©ÊõºóXelox·½°¸Í¬ÆÚÁªºÏÊÊÐε÷Ç¿·ÅÁƵÄÁÙ´²¹Û²ì_ÁÙ´²Ò½Ñ§×¨Òµ±ÏÒµÂÛÎÄ·¶ÎÄ ×÷Õߣº¶ÅС²¨ ÆѾ² ÕÔÕñ»ª ´÷ÌÃÖª Áζ«±ë ÀîÑ©ËÉ ÖÜóãÇï ÈÎËØÈØ Ä¿µÄ:ÆÀ¼Ûθ°©»¼ÕßÊõºóCapeOX·½°¸Í¬ÆÚÁªºÏµ÷Ç¿·ÅÁƵĽüÆÚÁÆЧºÍ¶¾ÐÔ·´Ó¦¡£·½·¨£º´Ó2007Äê9ÔÂÖÁ2010Äê9Ô£¬41Àýθ°©Êõºó»¼Õß²ÉÓû¯ÁƲÉÓÃXelox·½°¸£¬¿¨ÅàËû±õ1250 mg£¯m2 £¬¿Ú·þ(2´Î£¯d)£¬1-14d£»°ÂɳÀû²¬130 mg£¯m2£¬³ÖÐø¾²ÂöµÎ×¢2¡«3 h£¬1 d¡£Í¬²½ÊÊÐε÷Ç¿·ÅÁÆ£¬°ÐÇø°üÀ¨Áö´²ºÍÇøÓòÁÜ°ÍÒýÁ÷Çø¡£·Å»¯Áƺó¸¨Öú»¯ÁÆÒÔXelox·½°¸4¡«6ÁƳ̣¬¹Û²ì½üÆÚÁÆЧ¼°¶¾ÐÔ·´Ó¦¡£½á¹û£ºÈ«×é1 Äê×ÜÉú´æÂÊ¡¢ÎÞ¸´·¢Éú´æÂʺ;ֲ¿ÇøÓò¿ØÖÆÂÊ·Ö±ðΪ90£®2£¥ ¡¢80£®5£¥ºÍ95.1£¥ ¡£ÓÐ3ÀýÖжÏͬ²½·Å»¯ÁÆ¡£¢ó¶È¹ÇËèÒÖÖÆ4Àý£¬¢ó¶È賦µÀ·´Ó¦5Àý¡£½áÂÛ£ºÎ¸°©»¼ÕßÊõºóCapeOX·½°¸Í¬ÆÚÁªºÏµ÷Ç¿·ÅÁƵĽüÆÚÁÆЧ½ÏºÃ£¬¶¾ÐÔ·´Ó¦ÊÇ¿ÉÄÍÊܵġ£ θ°©;·ÅÁÆ;¿¨ÅàËû±õ;°ÂɳÀû²¬;¸±×÷Óà Objective;To evaluate the short-term efficacy and toxicity of Xelox plus concurrent conformal intensity modulated radiation therapy for postoperation patients with gastric cancer. Methods: Form September 2007 to September 2010, 41 postoperation gastric cancer patients were treated with Xelox plus concurrent conformal intensity modulated radiation therapy. The Xelox regimen was capecitabine 1250 mg/m2, orally bid, day1to 14, oxaliplatin 130 mg/m2, continuous infusion 2 to 3h, day1. Intensity modulated radiation therapy: target volume including the tumor bed and regional lymphatic drainage area, the radiation dose is 45GY/25 fractions. After chemoradiotherapy, those patients were treated with 4 to 6 cycles Xelox regimen. Efficacy and toxicity will be observed. Results: The 1-year overall survival, relapse-free survival and locoregional control rates of 41 patients were 90.2%, 80.5% and 95.1%. 3 patients interrupted chemoradiotherapy. ¢ó myelosuppression occurred in 4 cases and ¢ó degree of gastrointestinal toxicity occurred in in 5 cases. Conclusion: The short-term efficacy of Xelox plus concurrent conformal intensity modulated radiation therapy for postoperation patients with gastric cancer was good, and toxicity was tolerable. Gastric Cancer, Radiotherapy, Capecitabine, Oxaliplatin, Side Effects Ç°ÑÔ£º θ°©ÔÚÈ«ÇòµÄ·¢²¡ÂÊÅÅÔÚËùÓÐÖ×ÁöµÄµÚ4λ£¬Î¸°©ÊÇÎÒ¹ú×î³£¼ûµÄ¶ñÐÔÖ×ÁöÖ®Ò»£®Î¸°©ÄÐÅ®ÈË¿Úµ÷ÕûËÀÍöÂÊ£¨ÄÐÐÔ£º40.8/10Íò£¬Å®ÐÔ£º18.6/10Íò£¬ÄÐÐÔÊÇÅ®ÐÔµÄ1.9±¶£©·Ö±ðÊÇÅ·ÃÀ·¢´ï¹ú¼ÒµÄ4.2-7.9±¶ºÍ3.8-8.0±¶¡£ÉϺ£Î¸°©´ÖËÀÍöÂÊÄÐÐÔΪ52.24/10Íò£¬¾Ó¶ñÐÔÖ×Áö·¢²¡µÚ¶þλ£¬Å®ÐÔΪ29.26/10Íò£¬¾Ó¶ñÐÔÖ×ÁöµÄµÚÈýλ£Û1£Ý¡£¶àÊýθ°©»¼Õß¾ÍÕïʱÒÑ´¦ÓÚ½øÕ¹ÆÚ£¬ÔçÆÚθ°©±ÈÀý²»×ãl0£¥£¬ÒòΪÕï¶ÏʱÍíÆÚθ°©½Ï¶à£¬¾ö¶¨ÁËθ°©µÄÖÎÓúÂʽϵͣ¬ÔÚÃÀ¹ú£¬Î¸°©µÄ5ÄêÉú´æÂʲÅ24%¡£Ìá¸ßθ°©µÄÖÎÓúÂÊ£¬³ýÁËÔçÆÚÕï¶ÏÍ⣬¾ÍÊÇÀûÓÃÏÖÓеÄÊֶΣ¬½øÐкÏÀíµÄ½áºÏ£¬½øÒ»²½Ìá¸ßÁÆЧ£¬Í¬Ê±½µµÍ»ò²»Ôö¼Ó¸±×÷Óá£ θ°©µÄÊõºó·Å»¯ÁÆÊÇ¢ò¡¢¢óÆÚθ°©µÄ±ê×¼ÖÎÁÆ£¬Î¸°©µÄ·ÅÁƵļ¼ÊõºÍ¼ÁÁ¿¼°·Ö¸î·½Ê½ÒѾ­½Ï³ÉÊ죬µ«Êõºó»¯ÁƵķ½°¸ÉÏÎç±ê×¼·½°¸¡£ÎÒÃǶÔÎÒÔº2007Äê9ÔÂÖÁ2010Äê9ÔµÄ41Àýθ°©Êõºó½øÐÐXelox·½°¸Í¬ÆÚÁªºÏÊÊÐε÷Ç¿·ÅÁÆÖÎÁƵĻ¼ÕߵĽüÆÚÁÆЧ¼°¶¾ÐÔ·´Ó¦½øÐзÖÎöºÍ£¬±¨¸æÈçÏ¡£ 1 ×ÊÁÏÓë·½·¨ 1£®1 ÁÙ´²×ÊÁϱ¾×éÅ®12Àý¡¢ÄÐ29Àý£¬ÄêÁä42¡«66Ëꡢƽ¾ù59Ëê¡£AJCC·ÖÆÚ£¨µÚÁù°æ£©¢òÆÚ6Àý£¬¢óAÆÚ12Àý£¬¢óBÆÚ23Àý¡£ÏÙ°©37Àý¡¢Ó¡½äϸ°û°©4Àý¡£ËùÓв¡Ô±¾ùΪR0Çгý£¬Î¸´ó²¿Çгý37Àý¡¢È«Î¸Çгý4Àý¡£ÁܰͽáÇåɨ·¶Î§°üÀ¨Î¸ÖÜÁܰͽᡢƢ¶¯Âö¡¢¸Î¶¯Âö¡¢Î¸×ó¶¯ÂöºÍ¸¹Ö÷¶¯ÂöÅÔµÄÁܰͽáµÈ¡£ËùÓл¼Õß·Å»¯ÁÆÇ°KamofskyÆÀ·Ö60·Ö£¬°×ϸ°û4¡Á109 £¯L£¬Ñªºìµ°°×10g£¯L,ѪС°å80¡Á109£¯L£¬¸ÎÉö¹¦ÄÜ¡¢Ðĵçͼ¾ùÕý³£¡£ 1£®2 ÖÎÁÆ·½·¨: Xelox»¯ÁÆ·½°¸£º¿¨ÅàËû±õ1250 mg£¯m2£¬¿Ú·þ(2´Î£¯d)£¬1-14d£»°ÂɳÀû²¬130 mg£¯m2£¬³ÖÐø¾²ÂöµÎ×¢2¡«3 h£¬1 d£¬ÓÃÒ©Æڼ丨ÖúÒÔ¸ñÀ­Ë¾ÇíµÈֹͶÔÖ¢´¦Àí´ëÊ©¡£ ·ÅÁÆ£ºÊõºó4¡«8ÖÜÄÚ½øÐзÅÁÆ£¬·ÅÁÆÇ°ÈÈËÜĤ¹Ì¶¨£¬È»ºóÔöÇ¿CT¶¨Î»£¬ÔÙÓÉÒ½Éú¹´»­°ÐÇøºÍΣ¼°Æ÷¹Ù¡£CTV°üÀ¨Áö´²ºÍÇøÓòÁÜ°ÍÒýÁ÷Çø£¬Áö´²·¶Î§°üÀ¨Ö×Áö¡¢²Ðθ¡¢ÒÑÇгýµÄθԭËùÔÚÇø¼°Ò»²¿·Öºá½á³¦¡¢Ê®¶þÖ¸³¦¡¢ÒÈÏÙºÍÞ²Âö£¬»¹Ó¦°üÀ¨¿Õ³¦Ò»Î¸»ò¿Õ³¦Ò»Ê³¹ÜÎǺϿڣ»¸¹Ä¤ÔòÒª¸ù¾Ý¾Ö²¿½þÈóºÍÔ¶´¦×ªÒƵij̶ÈÀ´¿¼ÂÇ¡£CTVÓ¦°üÀ¨Î¸ËùÔڵĸ¹Ä¤Çø¡£ÁÜ°ÍÒýÁ÷ÇøÓò£º½ü¶ËÈý·ÖÖ®Ò»/êÚÃÅ/θʳ¹Ü½áºÏ²¿Ô­·¢°©¸ßΣÁܰͽáÇø°üÀ¨£ºÁÚ½üµÄʳ¹ÜÖÜΧ¡¢Î¸ÖÜ¡¢ÒÈÏÙÉÏ¡¢¸¹Ç»¸ÉÁܰͽáºÍÆ¢ÃÅÁܰͽáÇø¡£ÖÐÈý·ÖÖ®Ò»/θÌå°©¸ßΣÁܰͽáÇø°üÀ¨£ºÁÚ½üµÄθÖÜ¡¢ÒÈÏÙÉÏ¡¢¸¹Ç»¸É¡¢Æ¢ÃÅ¡¢¸ÎÃźÍÒÈÊ®¶þÖ¸³¦ÁܰͽᡣԶ¶ËÈý·ÖÖ®Ò»/θñ¼/ÓÄÃÅÔ­·¢°©¸ßΣÁܰͽáÇø°üÀ¨£ºÎ¸ÖÜ¡¢ÒÈÏÙÉÏ¡¢¸¹Ç»¸É¡¢¸ÎÃźÍÒÈÊ®¶þÖ¸³¦ÁܰͽᡣΣ¼°Æ÷¹Ù¼ÁÁ¿ÏÞ¶¨Îª£º¸ÎÔࣺ60%¸ÎÔà30 Gy£»ÉöÔࣺÖÁÉÙÒ»²àÉöÔàµÄ2/320 Gy£»¼¹Ë裺45 Gy£»ÐÄÔࣺ1/3ÐÄÔà50 Gy¡£²ÉÓõ÷Ç¿·ÅÁÆ£¬·ÅÁƼÁÁ¿ÎªPTV45 Gy£¯25´Î£¬5¡«7Ò°¡£ ·Å»¯Áƺó¸¨Öú»¯ÁÆÒÔXelox·½°¸4¡«6ÁƳ̡£ 1£®3 ÆÀ¼ÛÖ¸±ê: ¹Û²ì1 Äê×ÜÉú´æÂÊ¡¢ÎÞ¸´·¢Éú´æÂʺ;ֲ¿ÇøÓò¿ØÖÆÂÊ¡£¹Û²ì·Å»¯ÁƸ±×÷Óã¬Á˽âÖÎÁƵÄÄÍÊÜÐÔ£¬Ö÷Òª¹Û²ìѪҺ¶¾ÐÔ¡¢Î¸³¦µÀ¶¾ÐÔ¡¢Éñ¾­¶¾ÐÔ£¬°´RTOG£¯EORTC¼±ÐÔ·ÅÉä·´Ó¦ÆÀ·Ö±ê×¼½øÐÐÆÀ·Ö¡£ 2 ½á¹û 2£®1 Éú´æÂʺ͸´·¢×ªÒÆÇé¿ö±¾×éËæ·Ã12¡«36¸öÔ¡¢Æ½¾ù21¸öÔ£¬È«×é1 Äê90£®2£¥ ¡¢80£®5£¥ºÍ95.1£¥ ¡£ÓÐ3ÀýÖжÏͬ²½·Å»¯ÁÆ¡£Ëæ·ÃÆÚ¼ä½ö2Àý³öÏÖ·ÅÉäÒ°ÄÚ¾Ö²¿¸´·¢(1ÀýÁܰͽḴ·¢£¬1Àýµ¥´¿ÎǺϿڸ´·¢)£»6Àý³öÏÖÔ¶´¦×ªÒÆ¡£Ëæ·ÃÆÚÄÚËÀÍö4Àý£¬¾ùËÀÓÚθ°©¸´·¢»òתÒÆ¡£ 2£®2 ¶¾¸±·´Ó¦¼û±í1¡£ 3ÌÖÂÛ Íâ¿ÆÊÖÊõÊÇÔçÆÚθ°©µÄÖ÷ÒªÖÎÁÆ·½·¨£¬¶ÔÓÚÔçÆÚθ°©ÊÖÊõÇгýЧ¹ûºÃ¡£ÖС¢ÍíÆÚθ°©ËäÈ»ÊÖÊõ¿É×ö´ó²¿·Ö¡¢»ò¾Ö²¿Çгý£¬µ«ÓúºóЧ¹ûÈԺܲ5ÄêÉú´æÂÊÈÔÄÑÒÔÌá¸ß¡£×ÛºÏÖÎÁÆ¡¢¶àѧ¿Æ²ÎÓë¿ÉÌá¸ßθ°©µÄ5ÄêÉú´æÂÊ¡£
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö